New pill targets rare gene in Hard-to-Treat cancers
NCT ID NCT02122913
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment options left.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital of the University of Pennsylvania - Radiology
Philadelphia, Pennsylvania, 19104, United States
-
Mass General Cancer Center
Boston, Massachusetts, 02114, United States
-
OHSU Hospital - Neurology
Portland, Oregon, 97239, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas, 77030, United States
-
UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
UH Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
UPMC Mercy - Oncology
Pittsburgh, Pennsylvania, 15219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?